Biotek-snakken — December 2022
-
-
-
Retfærdigt kursfald på mere end 40 % til Ascelia Pharma?
Efter en periode med et kurscomeback blev det en brat opvågnen til Ascelia Pharma efter meddelelsen i sidste uge om ændringer i det vigtige fase 3 studie
Økonomisk Ugebrev (ugebrev.dk)
-
Godformiddag med lidt spændende fra pharma/biotek: "Analysts Say These 2 Stocks Could Double Your Money — Here’s Why They Could Surge"
-
Biotekaktien, der blev tredoblet i 2022, kan måske gå endnu højere i 2023
-
Is Biogen's Stock Too Risky to Invest in? https://www.proinvestor.com/investornyt/920686/is-biogens-stock-too-risky-to-invest-in
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind